Targeting Colon Cancer with a New Enzyme Therapy
Author Information
Author(s): Oosterhoff D, Pinedo H M, van der Meulen I H, de Graaf M, Sone T, Kruyt F A, van Beusechem V W, Haisma H J, Gerritsen W R
Primary Institution: Vrije Universiteit Medical Center
Hypothesis
Extracellular conversion of the prodrug CPT-11 into its active form will enhance the bystander effect in treating colon cancer.
Conclusion
The study successfully constructed a secreted form of carboxylesterase that activates the prodrug CPT-11, leading to increased toxicity against colon cancer cells.
Supporting Evidence
- Both secreted forms of carboxylesterase showed enzyme activity and effectively activated CPT-11.
- The fusion protein C28-sCE2 specifically bound to EpCAM expressing colon cancer cells.
- Incubation with the secreted enzymes and CPT-11 resulted in significant growth inhibition of colon cancer cells.
Takeaway
Scientists created a special enzyme that helps turn a cancer medicine into a stronger version that can kill more cancer cells. This could help treat colon cancer better.
Methodology
The study involved constructing and testing a secreted form of carboxylesterase and its fusion with a specific antibody to enhance drug activation in colon cancer cells.
Limitations
The study does not provide in vivo evidence to confirm the advantages of the targeted enzyme over the non-targeted version.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website